Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes. [PDF]
Nat CommunLiao KM, Wu JY, Lai CC.
europepmc +1 more source
Glucagon-like peptide-1 receptor agonists and venous thromboembolism: an unresolved question for Australian prescribers. [PDF]
Intern Med JKamel KS, Chan D, Hovelroud R.
europepmc +1 more source
Use of glucagon-like peptide-1 receptor agonists is associated with inadequate bowel preparation for colonoscopy in patients with diabetes. [PDF]
J Diabetes InvestigOgawa O.
europepmc +1 more source
Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity. [PDF]
J Neurol SciChen H +8 more
europepmc +1 more source
Glucagon-like-peptide-1 receptor agonists in the intensive care unit: practical implications for the intensivists. [PDF]
Crit Care SciBianchini L, Martins GAR, Myatra SN.
europepmc +1 more source
Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia. [PDF]
CureusLópez-Ibor I, Humphery H, Tafet G.
europepmc +1 more source
Glucagon-Like Peptide-1 Receptor Agonist-Based Agents and Body Composition: Filling More Gaps. [PDF]
Obesity (Silver Spring)Dubin RL +4 more
europepmc +1 more source
Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence. [PDF]
Ophthalmol RetinaHallaj S +6 more
europepmc +1 more source
Glucagon-Like Peptide-1 Receptor Agonists: Considerations for Treating Preconception Obesity. [PDF]
Obesity (Silver Spring)Berube LT +4 more
europepmc +1 more source
Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study. [PDF]
Diabetes Obes MetabMatsuo Y +3 more
europepmc +1 more source